About: Heart Transplantation in the Era of the SARS‐CoV‐2 Pandemic: Is It Safe and Feasible?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Heart Transplantation in the Era of the SARS‐CoV‐2 Pandemic: Is It Safe and Feasible? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Heart Transplantation in the Era of the SARS‐CoV‐2 Pandemic: Is It Safe and Feasible?
Creator	Kobashigawa, Jon Bs, Gabriel Chikwe, Joanna Czer, Lawrence Emerson, Dominic Esmailian, Fardad Ja, Kobashigawa Jk, Patel Megna, Dominick Nishihara Bs, Keith Patel, Jignesh Ramzy, Danny Transplant, Clin Trento, Alfredo
Source	Medline; PMC
abstract	As the SARS‐CoV‐2 pandemic continues to unfold, the number of heart transplants completed in the United States has been declining steadily. The current case series examines the immediate short‐term outcomes of 7 heart transplant recipients transplanted during the SARS‐CoV‐2 pandemic. We hope to illustrate that with proper preparation, planning, and testing, heart transplantation can be continued during a pandemic. We assessed 7 patients transplanted from March 4, 2020 to April 15, 2020. The following endpoints were noted: in‐hospital survival, in‐hospital freedom from rejection, in‐hospital non‐fatal major cardiac adverse events (NF‐MACE), severe primary graft dysfunction, hospital length of stay, and ICU length of stay. There were no expirations throughout the hospital admission. In addition, there were no patients with NF‐MACE or treated rejection, and 1 patient developed severe primary graft dysfunction. Average length of stay was 17.2 days with a standard deviation of 5.9 days. ICU length of stay was 7.7 days with a standard deviation of 2.3 days. Despite the decreasing trend in completed heart transplants due to SARS‐CoV‐2, heart transplantation appears to be feasible in the immediate short term. Further follow up is needed, however, to assess the impact of SARS‐CoV‐2 on post‐heart transplant outcomes months after transplantation.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1111/ctr.14029
bibo:pmid	32633819
has license	no-cc
sha1sum (hex)	b416787234934927f6fe3fe706444f02317996a1
schema:url	https://doi.org/10.1111/ctr.14029
resource representing a document's title	Heart Transplantation in the Era of the SARS‐CoV‐2 Pandemic: Is It Safe and Feasible?
has PubMed Central identifier	PMC7361065
has PubMed identifier	32633819
schema:publication	Clin Transplant
resource representing a document's body	covid:b416787234934927f6fe3fe706444f02317996a1#body_text
is schema:about of	named entity 'severe' named entity 'length' named entity 'addition' named entity 'Safe' named entity 'SARS-CoV-2' named entity 'Pandemic' named entity 'OUTCOMES' named entity 'PREPARATION' named entity 'ADVERSE EVENTS' named entity 'CASE SERIES' named entity 'HOPE' named entity 'ADDITION' named entity 'AVERAGE' named entity 'patients' named entity 'Further' named entity 'hospital' named entity 'length' named entity 'needed' named entity 'SARS-CoV-2' named entity 'adverse events' named entity 'heart transplants' named entity 'pandemic' named entity 'heart transplants' named entity 'endpoints' named entity 'SARS-CoV-2' named entity 'heart transplant' named entity 'heart transplant' named entity 'heart transplantation' named entity 'standard deviation' named entity 'United States' named entity 'adverse events' named entity 'Heart Transplantation' named entity 'elective surgeries' named entity 'single center' named entity 'case series' named entity 'SARS-CoV-2' named entity 'immunosuppressive medication' named entity 'operating room' named entity 'pacemaker' named entity 'PGD' named entity 'H1N1' named entity 'bacterial infection' named entity 'heart transplants' named entity 'primary graft dysfunction' named entity 'standard deviation' named entity 'SARS-CoV-2' named entity 'liver' named entity 'SARS-CoV-2' named entity 'standard deviation' named entity 'PGD' named entity 'antibody' named entity 'case series' named entity 'data analysis' named entity 'organ transplantation' named entity 'data analysis' named entity 'kidney transplants' named entity 'transplant recipients' named entity 'sternotomy' named entity 'California' named entity 'heart transplantation' named entity 'immunosuppression' named entity 'sternotomy' named entity 'heart transplantation' named entity 'State of Emergency' named entity 'United States' named entity 'stroke' named entity 'kidney transplant' named entity 'influenza'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software